Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and ...

in 2018 as the first treatment for hemophagocytic lymphohistiocytosis. In July 2019, Novimmune divested Gamifant and related activities, and rebranded as Light Chain Bioscience with a focus on ...

In 2018, Sobi acquired the global rights to emapalumab, the first and only treatment for primary hemophagocytic lymphohistiocytosis (HLH), recently approved for the treatment of primary HLH in the US.

A number of clinical and virological insights into CCHF have been revealed. Virus-associated hemophagocytic syndrome has been found to contribute to the exacerbation of CCHF in some patients ...

LOUISVILLE, Ky. -- A CD70-targeted CAR T-cell therapy for advanced kidney cancer continued to show durable activity in ...

Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and ...

I just look back and say, 'Thank God I made it through.' As a toddler in Cincinnati, Ohio, William was diagnosed with hemophagocytic lymphohistiocytosis, a rare, life-threatening disorder in which the ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS): In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, HLH/MAS occurred in 2.9% (10/349) of patients.

IEC-HS includes the preferred terms IEC-HS, HLH, Hemophagocytic lymphohistiocytosis, and atypical HLH. Two patients developed an inflammatory syndrome prior to the existence of IEC-HS as a term in ...

In the US, emapalumab-lzsg is indicated for pediatric (newborn and older) and adult primary hemophagocytic lymphohistiocytosis (HLH) patients with refractory, recurrent or progressive disease, or ...